文献速递胸部肿瘤

肺气肿是晚期NSCLC合并COPD接受免疫检查点抑制剂治疗的预后因素

Brief Report: Emphysema as a Prognostic Factor in Patients With Advanced NSCLC With COPD Receiving Immune Checkpoint Inhibitors.
PubMed 文献 · J Thorac Oncol · 2025-10-21

本研究纳入2013至2024年接受单药免疫检查点抑制剂一线或二线治疗的111例晚期NSCLC合并COPD患者,按胸部CT视觉评估分为合并肺气肿组(77例)与无肺气肿组。合并肺气肿组总生存显著更长(17.3 vs 8.5个月,p=0.008),多因素分析显示肺气肿为更好OS的独立因素(HR 0.49;95%CI 0.30-0.81)。

要点

  • 合并COPD的晚期NSCLC患者中,CT视觉检出肺气肿与免疫治疗后更长的OS相关。
  • 肺气肿为更好OS的独立预后因素(HR 0.49;95%CI 0.30-0.81)。
  • 肺气肿状态不影响不良事件发生率(p=0.455)。

核心结论

  • 胸部CT视觉检出的肺气肿可能是晚期NSCLC合并COPD患者接受ICIs治疗的潜在预后标志物。

研究设计与样本

  • 回顾性研究纳入2013至2024年接受单药ICI一线或二线治疗的111例经肺功能确诊COPD的晚期NSCLC患者。
  • 按胸部CT视觉评估是否合并肺气肿分组,其中77例合并肺气肿。

主要发现

  • 合并肺气肿组中位OS为17.3个月,无肺气肿组为8.5个月(p=0.008)。
  • 无进展生存有改善趋势但无统计学意义(3.3 vs 2.4个月,p=0.641)。
  • 多因素分析显示肺气肿为更好OS的独立因素(HR 0.49;95%CI 0.30-0.81)。
  • 不良事件发生率在有无肺气肿组间相似(p=0.455)。

临床怎么用

  • 在晚期NSCLC合并COPD患者中,可结合胸部CT视觉评估肺气肿辅助预后判断。
  • 肺气肿的存在不应作为排除ICI治疗的依据。

局限性

  • 样本量有限(111例),需进一步研究确认这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Chronic obstructive pulmonary disease (COPD) and emphysema are independent risk factors for lung cancer development and have been independently associated with longer overall survival (OS) in patients with NSCLC treated with immune checkpoint inhibitors (ICIs). However, their combined impact on prognosis remains unclear. This study evaluates emphysema as a prognostic factor in patients with COPD with advanced NSCLC (aNSCLC) undergoing immunotherapy. METHODS: This study included patients with aNSCLC with COPD (defined by spirometry) treated with single-agent ICI as first- or second-line treatment, from 2013 to 2024. Patients were classified based on visually detected emphysema on chest computed tomography. RESULTS: The study included 111 patients with COPD, of whom 77 had coexisting emphysema. Patients with COPD and emphysema had significantly longer OS compared with those without emphysema (17.3 versus 8.5 mo, p = 0.008), with a nonsignificant trend toward improved progression-free survival (3.3 versus 2.4 mo, p = 0.641). Emphysema remained an independent factor of better OS in multivariate analysis (hazard ratio: 0.49; 95% confidence interval: 0.30-0.81). Adverse event rates were similar regardless of emphysema status (p = 0.455). CONCLUSIONS: This study suggests that visually detected emphysema on chest computed tomography could be a potential prognostic marker in patients with aNSCLC with COPD receiving ICIs. Further studies are guaranteed to confirm these findings.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Di Frisco M, Sanmamed MF, Ferrández JM, et al. Brief Report: Emphysema as a Prognostic Factor in Patients With Advanced NSCLC With COPD Receiving Immune Checkpoint Inhibitors. J Thorac Oncol. 2025. PMID: 41130410. doi:10.1016/j.jtho.2025.10.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。